Fundamentals of immunology for understanding immunotherapy for lymphoma
Tóm tắt
An effective antitumor immune response in patients with lymphoma would eradicate the malignant B cells and cure the patient of the disease. This, however, does not occur, and a suboptimal antitumor response results in persistence and subsequent progression of the patient’s disease. The goals of immunotherapy are therefore to restore an effective antitumor immune response by promoting immune recognition, optimizing immune activation, and supporting persistence of the immune response resulting in subsequent immunological memory. Multiple mechanisms, however, are present within the tumor microenvironment that account for an inadequate immune response. These include loss of major histocompatibility complex expression on tumor cells and subsequent inadequate antigen presentation, increased expression of immunosuppressive ligands on malignant cells, populations of immune cells with suppressive function present in the tumor, and cytokines secreted by the malignant cell or other cells in the microenvironment that promote immune exhaustion or suppress the immune response. Successful immunotherapeutic strategies are specifically addressing these issues by promoting antigen presentation, improving recognition of the malignant cell, directly activating T cells and natural killer cells, and blocking immune checkpoint signaling that would suppress the immune response. Many of these approaches have proven highly successful in patients with various subtypes of lymphoma and are now being incorporated into standard clinical practice.
Tài liệu tham khảo
Moser, 2010, Key concepts in immunology, Vaccine, 28, C2, 10.1016/j.vaccine.2010.07.022
Cronkite, 2018, The regulation of inflammation by innate and adaptive lymphocytes, J Immunol Res, 2018, 1467538, 10.1155/2018/1467538
Courtney, 2018, TCR signaling: mechanisms of initiation and propagation, Trends Biochem Sci, 43, 108, 10.1016/j.tibs.2017.11.008
Alegre, 2001, T-cell regulation by CD28 and CTLA-4, Nat Rev Immunol, 1, 220, 10.1038/35105024
Murakami, 2014, Co-inhibitory pathways and their importance in immune regulation, Transplantation, 98, 3, 10.1097/TP.0000000000000169
Walunas, 1994, CTLA-4 can function as a negative regulator of T cell activation, Immunity, 1, 405, 10.1016/1074-7613(94)90071-X
Keir, 2008, PD-1 and its ligands in tolerance and immunity, Annu Rev Immunol, 26, 677, 10.1146/annurev.immunol.26.021607.090331
Kline, 2020, The immune landscape and response to immune checkpoint blockade therapy in lymphoma, Blood, 135, 523, 10.1182/blood.2019000847
Tarte, 2017, Role of the microenvironment across histological subtypes of NHL, Hematology Am Soc Hematol Educ Program, 2017, 610, 10.1182/asheducation-2017.1.610
Cader, 2018, Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment, Blood, 132, 825, 10.1182/blood-2018-04-843714
Yang, 2019, Mass cytometry analysis reveals that specific intratumoral CD4+ T cell subsets correlate with patient survival in follicular lymphoma, Cell Rep, 26, 2178, 10.1016/j.celrep.2019.01.085
Roemer, 2016, Classical Hodgkin lymphoma with reduced β2M/MHC class I expression is associated with inferior outcome independent of 9p24.1 status, Cancer Immunol Res, 4, 910, 10.1158/2326-6066.CIR-16-0201
Roemer, 2018, Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma, J Clin Oncol, 36, 942, 10.1200/JCO.2017.77.3994
Rimsza, 2004, Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project, Blood, 103, 4251, 10.1182/blood-2003-07-2365
Roberts, 2006, Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival, Blood, 108, 311, 10.1182/blood-2005-11-4742
Rybski, 1991, Prediction of outcome in diffuse large cell lymphoma by the major histocompatibility complex class II (HLA-DR, DP, DQ) and class I (HLA-A, B, C) phenotype, Leuk Lymphoma, 6, 31, 10.3109/10428199109064876
Booman, 2006, Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma, Clin Cancer Res, 12, 2698, 10.1158/1078-0432.CCR-05-2617
Green, 2012, Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy, Clin Cancer Res, 18, 1611, 10.1158/1078-0432.CCR-11-1942
Steidl, 2011, MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers, Nature, 471, 377, 10.1038/nature09754
Roemer, 2016, PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome, J Clin Oncol, 34, 2690, 10.1200/JCO.2016.66.4482
Chen, 2013, PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies, Clin Cancer Res, 19, 3462, 10.1158/1078-0432.CCR-13-0855
Josefsson, 2019, TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma, Cancer Immunol Res, 7, 355, 10.1158/2326-6066.CIR-18-0351
Yang, 2012, IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma, J Clin Invest, 122, 1271, 10.1172/JCI59806
Keane, 2020, LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma, Blood Adv, 4, 1367, 10.1182/bloodadvances.2019001390
Aoki, 2020, Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma, Cancer Discov, 10, 406, 10.1158/2159-8290.CD-19-0680
Yang, 2007, CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells, Blood, 110, 2537, 10.1182/blood-2007-03-082578
Wilcox, 2009, Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells, Blood, 114, 2936, 10.1182/blood-2009-05-220111
Carey, 2017, Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma, Blood, 130, 2420, 10.1182/blood-2017-03-770719
Azzaoui, 2016, T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells, Blood, 128, 1081, 10.1182/blood-2015-08-662783
Xiu, 2015, IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphoma, Blood Cancer J, 5, e328, 10.1038/bcj.2015.56
Yang, 2014, TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin’s lymphoma, Leukemia, 28, 1872, 10.1038/leu.2014.84
Armand, A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies [published online ahead of print 29 June 2020], Leukemia
Ansell, 2020, Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies, Blood Adv, 4, 1917, 10.1182/bloodadvances.2019001079
Gopal, 2020, First-in-human study of utomilumab, a 4-1BB/CD137 agonist, in combination with rituximab in patients with follicular and other CD20+ non-Hodgkin lymphomas, Clin Cancer Res, 26, 2524, 10.1158/1078-0432.CCR-19-2973
Viardot, 2016, Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma, Blood, 127, 1410, 10.1182/blood-2015-06-651380
Rothe, 2015, A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma, Blood, 125, 4024, 10.1182/blood-2014-12-614636
Kallam, 2019, Recent advances in CAR-T cell therapy for non-Hodgkin lymphoma, Clin Lymphoma Myeloma Leuk, 19, 751, 10.1016/j.clml.2019.09.598
Houot, 2009, Vaccines for lymphomas: idiotype vaccines and beyond, Blood Rev, 23, 137, 10.1016/j.blre.2008.09.001
Liu, 2015, CD47 blockade triggers T cell-mediated destruction of immunogenic tumors, Nat Med, 21, 1209, 10.1038/nm.3931
Advani, 2018, CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma, N Engl J Med, 379, 1711, 10.1056/NEJMoa1807315